Advertisement

Biogen Idec (Nasdaq: BIIB) and Abbott Laboratories (NYSE: ABT) are reporting positive results for a Phase 2b study on a potential therapy for Relapsing-Remitting Multiple Sclerosis.

Weston-based Biogen and Abbott Park, Ill.-based Abbott said that the drug candidate, delivered under the skin once a month, reduced the annualized relapse rate by 54 percent in the lower-dose group of patients and 50 percent in the higher-dose group of patients, versus a placebo. The trial also found that the potential therapy, called dalcizumab HYP, slowed disability progression for patients.

SOURCE

Advertisement
Advertisement